Business Context and Reporting Period
Company: Scinai Immunotherapeutics Ltd. (formerly Biondvax Pharmaceuticals Ltd.)
Filing Type: Form 6-K (Report of Foreign Private Issuer)
Date: September 6, 2023
Reporting Period: Month of September 2023
The filing serves to make available an updated business presentation (Exhibit 99.1) to investors. The registrant is headquartered in Jerusalem, Israel, and files annual reports on Form 20-F.
Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. This document is a procedural filing to distribute a presentation rather than a financial statement.
Material Changes
No material financial changes or operational updates are detailed within the text of this specific filing. The primary update is the release of the September 2023 business presentation.
Guidance, Outlook, and Risks
Management Commentary: The Company states that the information in the attached presentation is summary in nature. It explicitly notes that the presentation is not an admission as to the materiality of any information contained therein.
Contextual Warning: Investors are advised to consider the presentation in the context of the Company's other SEC filings and public announcements.
Key Facts for Investor Verification
- Review the attached Exhibit 99.1 (Scinai Immunotherapeutics Presentation dated September 2023) for detailed business updates.
- Verify that the summary information in the presentation aligns with the Company's most recent audited financial statements and other public disclosures.
- Note the Company's former name was Biondvax Pharmaceuticals Ltd.